Filing Flows › ClearPoint Neuro (CLPT) › Q4 2025
ClearPoint Neuro (CLPT) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 17, 2026
ClearPoint Neuro (CLPT) reported revenue of $10.4M for the fourth quarter 2025 (Q4 2025), +34% from a year earlier and +17% from the quarter before. Operating margin was -67.7%, net loss $7.8M (74.8% of revenue).
ClearPoint Neuro, Q4 2025: revenue $10.4M (+34% year over year), operating margin -67.7%, net loss $7.8M, operating cash flow −$12.1M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.4M | +17% | +34% |
| Operating profit | −$7.0M | — | — |
| Net earnings | −$7.8M | — | — |
| Operating cash flow | −$12.1M | — | — |
What changed
Revenue was $10.4M in Q4 2025, up 34% year over year and up 17% from the previous quarter. Neurosurgery Navigation and Therapy Disposable Products was the largest line at 45% of revenue.
Gross margin was 61.5%, up 0.2 points from a year earlier. Operating costs exceeded revenue by $7.0M, an operating margin of -67.7%. Operating expenses grew 29% against revenue growth of 34%. The fastest-growing cost line was SG&A (+67%). The quarter ended with a net loss of $7.8M, wider than the previous quarter's $5.9M loss.
Operating cash flow was −$12.1M. Non-cash charges added back $249K of depreciation and amortization and $2.0M of share-based compensation. Working capital and other items used $6.5M. Capital expenditures of $49K exceeded it, leaving free cash flow of −$12.1M.
Questions
What was ClearPoint Neuro's revenue in the fourth quarter 2025?
ClearPoint Neuro (CLPT) reported revenue of $10.4M for the fourth quarter 2025 (Q4 2025), +34% from a year earlier and +17% from the quarter before.
Was ClearPoint Neuro profitable in the fourth quarter 2025?
Operating loss was $7.0M (-67.7% of revenue) and net loss $7.8M.
Source: ClearPoint Neuro 10-K on SEC EDGAR.